375 related articles for article (PubMed ID: 35982318)
1. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
2. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
3. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
4. Romosozumab for the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
[TBL] [Abstract][Full Text] [Related]
5. Effects of sclerostin antibodies in animal models of osteoporosis.
Ominsky MS; Boyce RW; Li X; Ke HZ
Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin: from bench to bedside.
Tanaka S; Matsumoto T
J Bone Miner Metab; 2021 May; 39(3):332-340. PubMed ID: 33206222
[TBL] [Abstract][Full Text] [Related]
7. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
8. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
10. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
11. Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis.
Joeng KS; Lee YC; Lim J; Chen Y; Jiang MM; Munivez E; Ambrose C; Lee BH
J Clin Invest; 2017 Jun; 127(7):2678-2688. PubMed ID: 28628032
[TBL] [Abstract][Full Text] [Related]
12. Romosozumab: from basic to clinical aspects.
Minisola S
Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
[TBL] [Abstract][Full Text] [Related]
13. Application of anti-Sclerostin therapy in non-osteoporosis disease models.
Jacobsen CM
Bone; 2017 Mar; 96():18-23. PubMed ID: 27780792
[TBL] [Abstract][Full Text] [Related]
14. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Canalis E
Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
[TBL] [Abstract][Full Text] [Related]
15. Profile of romosozumab and its potential in the management of osteoporosis.
Lim SY; Bolster MB
Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
17. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone: An Experimental Study in Nonhuman Primates.
Florio M; Kostenuik PJ; Stolina M; Asuncion FJ; Grisanti M; Ke HZ; Ominsky MS
J Bone Joint Surg Am; 2023 Aug; 105(15):1145-1155. PubMed ID: 37159527
[TBL] [Abstract][Full Text] [Related]
18. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
[TBL] [Abstract][Full Text] [Related]
19. The Regulation of Bone Metabolism and Disorders by Wnt Signaling.
Maeda K; Kobayashi Y; Koide M; Uehara S; Okamoto M; Ishihara A; Kayama T; Saito M; Marumo K
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698687
[TBL] [Abstract][Full Text] [Related]
20. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.
Rossini M; Gatti D; Adami S
Calcif Tissue Int; 2013 Aug; 93(2):121-32. PubMed ID: 23748710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
